European Heart Journal最新文献

筛选
英文 中文
Implementation of cardiac magnetic resonance imaging in everyday cardiology practice 心脏磁共振成像在日常心脏病学实践中的应用
IF 39.3 1区 医学
European Heart Journal Pub Date : 2026-09-30 DOI: 10.1093/eurheartj/ehag678
Sarah Moharem-Elgamal, Anna Baritussio, Ruxandra Christodorescu, Marc Ferrini, Giovanni Benfari, Fabrizio Ricci, Filipa Xavier Valente, José F Rodríguez Palomares, Gianluca Pontone, Stefano Nistri
{"title":"Implementation of cardiac magnetic resonance imaging in everyday cardiology practice","authors":"Sarah Moharem-Elgamal, Anna Baritussio, Ruxandra Christodorescu, Marc Ferrini, Giovanni Benfari, Fabrizio Ricci, Filipa Xavier Valente, José F Rodríguez Palomares, Gianluca Pontone, Stefano Nistri","doi":"10.1093/eurheartj/ehag678","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag678","url":null,"abstract":"Cardiac magnetic resonance (CMR) plays an established role in the assessment of cardiac patients. In this document, the aim is to demonstrate and clarify the role of CMR in the clinical management of heart disease for general cardiologists in everyday clinical practice. This document will cover the clinical indications, prognostic values, and limitations of CMR in the diagnosis and follow-up of heart disease, including ischaemic heart disease, heart failure, cardiomyopathies, valvular heart disease, aortopathies, cardiac masses, pericardial conditions, and adult congenital heart disease. This document also provides a basic understanding of the use of different CMR sequences and how cardiac function is assessed. With the increasing number of patients with cardiac implantable electronic devices, a brief understanding and advice on the use of CMR in this growing patient population who may need a scan during their lifetime is discussed. This document outlines the clinical applications of CMR and its use in everyday clinical practice for cardiologists who are not experts in CMR.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"16 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute cellular rejection after heart transplantation: validation of HEARTBiT, a transcriptomic biomarker. 心脏移植后的急性细胞排斥反应:验证HEARTBiT,一个转录组生物标志物。
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-29 DOI: 10.1093/eurheartj/ehag751
Casey P Shannon, Sara Assadian, Ashwini Rajasekaran, Chengliang Yang, Estefanía Espín, Le Lam, Robert Balshaw, Michael A Seidman, Chi K Lai, Heather J Ross, Marshall P Hyden, Sharon S Y Chih, Mustafa Toma, Bruce M McManus, Raymond T Ng, Scott J Tebbutt
{"title":"Acute cellular rejection after heart transplantation: validation of HEARTBiT, a transcriptomic biomarker.","authors":"Casey P Shannon, Sara Assadian, Ashwini Rajasekaran, Chengliang Yang, Estefanía Espín, Le Lam, Robert Balshaw, Michael A Seidman, Chi K Lai, Heather J Ross, Marshall P Hyden, Sharon S Y Chih, Mustafa Toma, Bruce M McManus, Raymond T Ng, Scott J Tebbutt","doi":"10.1093/eurheartj/ehag751","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag751","url":null,"abstract":"<p><strong>Background and aims: </strong>Acute cellular rejection (ACR) risk is highest within 60 days of heart transplantation (HTx), yet existing minimally invasive surveillance tools lack validation for this high-risk period. This study prospectively validated the diagnostic accuracy of HEARTBiT, a transcriptomic biomarker for detecting moderate-to-severe ACR, including during the early post-operative period.</p><p><strong>Methods: </strong>This prospective diagnostic accuracy study (NCT03575910) enrolled consecutive adult HTx recipients at four tertiary clinical centres. The diagnostic performance of HEARTBiT was evaluated in 336 visits from 117 participants against centralized expert consensus panel endomyocardial biopsy grades. An exploratory analysis of 246 serial visits from 31 participants evaluated the prognostic potential of tracking individual transcriptomic trajectories over time.</p><p><strong>Results: </strong>HEARTBiT accurately detected moderate-to-severe ACR (ISHLT ≥2R) with an overall area under the curve (AUC) of 0.78 [95% confidence interval (CI) 0.70-0.86]. Performance was stable early post-HTx (≤60 days: AUC = 0.78, 95% CI 0.65-0.90) and beyond 60 days (AUC = 0.80, 95% CI 0.72-0.87). Prioritizing high sensitivity (89% early, 100% late; corresponding to ≤1 missed ACR overall) yielded a specificity of 56% in the early period (≤60 days) and 49% beyond 60 days using the pre-specified cutoff (>0.54). Alternatively, adopting an exploratory time-varying threshold (>0.68) beyond 60 days yielded 83% sensitivity and 76% specificity. Importantly, HEARTBiT scores increased weeks before histological detection of ACR by tissue biopsy (slope-based AUC = 0.78, 95% CI 0.60-0.96).</p><p><strong>Conclusions: </strong>HEARTBiT provides a reliable, minimally invasive rule-out signal for moderate-to-severe ACR across the first year post-HTx, particularly during the high-risk early post-operative period. Serial tracking of HEARTBiT score trajectories has potential for prognosis of progression to ACR. These findings support the clinical utility of this biomarker in safely sparing more than 50% of protocol surveillance endomyocardial biopsies.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microaxial flow pump in high-risk PCI: proof of promise? 微轴流泵用于高风险PCI:前景证明?
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-29 DOI: 10.1093/eurheartj/ehag719
Ingo Eitel, Thomas Stiermaier
{"title":"Microaxial flow pump in high-risk PCI: proof of promise?","authors":"Ingo Eitel, Thomas Stiermaier","doi":"10.1093/eurheartj/ehag719","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag719","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary thrombosis with transiently increased pericoronary adipose tissue attenuation following parvovirus B19 infection. 细小病毒B19感染后冠状动脉血栓形成伴冠状动脉周围脂肪组织衰减短暂增加。
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-29 DOI: 10.1093/eurheartj/ehag807
Haruta Kato, Takahiro Kanda, Kei Tawarahara
{"title":"Coronary thrombosis with transiently increased pericoronary adipose tissue attenuation following parvovirus B19 infection.","authors":"Haruta Kato, Takahiro Kanda, Kei Tawarahara","doi":"10.1093/eurheartj/ehag807","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag807","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-TAVI FFR: a continuum between epicardial and microvascular physiology. tavi后FFR:心外膜和微血管生理之间的连续体。
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-29 DOI: 10.1093/eurheartj/ehag779
Flavio L Ribichini, Roberto Scarsini, Giuseppe Tarantini
{"title":"Post-TAVI FFR: a continuum between epicardial and microvascular physiology.","authors":"Flavio L Ribichini, Roberto Scarsini, Giuseppe Tarantini","doi":"10.1093/eurheartj/ehag779","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag779","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What does fractional flow reserve measure after transcatheter aortic valve implantation? 经导管主动脉瓣植入术后的分数血流储备测量是什么?
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-29 DOI: 10.1093/eurheartj/ehag777
Francesco Tona
{"title":"What does fractional flow reserve measure after transcatheter aortic valve implantation?","authors":"Francesco Tona","doi":"10.1093/eurheartj/ehag777","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag777","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes. 西马鲁肽对2型糖尿病患者骨髓驱动的循环炎性单核细胞的潜在减少作用。
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-29 DOI: 10.1093/eurheartj/ehag627
Charlotte J Teunis, Thomas J C Collins, Reindert F Oostveen, Annette E Neele, Menno de Winther, Nick S Nurmohamed, Jarom Heijmans, Maaike Winkelmeijer, Kim E Dzobo, Mark E Cooper, Daniël H van Raalte, Max Nieuwdorp, Hein J Verberne, Erik S G Stroes, Andrew J Murphy, Jeffrey Kroon, Nordin M J Hanssen
{"title":"Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes.","authors":"Charlotte J Teunis, Thomas J C Collins, Reindert F Oostveen, Annette E Neele, Menno de Winther, Nick S Nurmohamed, Jarom Heijmans, Maaike Winkelmeijer, Kim E Dzobo, Mark E Cooper, Daniël H van Raalte, Max Nieuwdorp, Hein J Verberne, Erik S G Stroes, Andrew J Murphy, Jeffrey Kroon, Nordin M J Hanssen","doi":"10.1093/eurheartj/ehag627","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag627","url":null,"abstract":"<p><strong>Background and aims: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular disease (CVD) in type 2 diabetes (T2D) and have anti-inflammatory effects in experimental studies, but their mechanism of action in humans remains unclear. This study characterized the cardiovascular-haematopoietic axis in individuals with T2D receiving semaglutide, as a potential mediator of GLP-1RA cardioprotective properties.</p><p><strong>Methods: </strong>In 16 individuals with T2D [63.2 ± 6.1 years, 37.5% female, weight 82.3 ± 15.3 kg, body mass index (BMI) 28.33 ± 3.5 kg/m2, LDL cholesterol 2.2 ± 0.9 mmol/L, glycated haemoglobin (HbA1c) 78.1 ± 13.1 mmol/mol, high-sensitivity C-reactive protein (hsCRP) 1.9 (1.2, 5.8) mg/L], blood and sternal bone marrow aspirates (subset, n = 14) were collected at baseline and after 6 months of semaglutide ≤2.0 mg weekly. Circulating monocytes and haematopoietic precursors were quantified by flow cytometry, plasma cytokines using an nELISA™ assay (Nomic Bio) and inflammatory macrophages in coronary arteries, bone marrow, and spleen by gallium-68-labelled DOTA-(Tyr3)-octreotate (68Ga-DOTATATE) positron emission tomography-computed tomography scans.</p><p><strong>Results: </strong>After 6 months of semaglutide, significant reductions in HbA1c (-21.1 mmol/mol, P < .0001), weight (-6.7 kg, P < .001), BMI (-2.5 kg/m2, P < .001), and hsCRP (-1.0 mg/L, P = .005) were observed. Circulating CD16+ monocytes were markedly lower (-18.8%, P = .034), with increased bone marrow retention correlating with weight loss, alongside reductions in interleukin-1 receptor antagonist, leptin, E-selectin, intercellular adhesion molecule-1 (ICAM-1), C-C motif chemokine ligand 2, C-C motif chemokine ligand 11, and C-X-C motif chemokine ligand 13. Gallium-68-labelled DOTA-(Tyr3)-octreotate PET-CT showed lower bone marrow uptake (-17.5%, P = .037), but not in spleen or coronary arteries.</p><p><strong>Conclusions: </strong>Semaglutide in T2D potentially reduces circulating inflammatory monocytes, increases bone marrow retention, and lowers markers of endothelial inflammation, with no reduction in coronary artery inflammatory macrophages. Semaglutide is associated with lower bone marrow 68Ga-DOTATATE uptake, which may relate to anti-inflammatory effects relevant to CVD risk.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement. 更正:儿童和青少年家族性高胆固醇血症:欧洲动脉粥样硬化学会共识声明。
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-29 DOI: 10.1093/eurheartj/ehag759
{"title":"Correction to: Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.","authors":"","doi":"10.1093/eurheartj/ehag759","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag759","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TMAO and abdominal aortic aneurysm: temporal alignment, baseline disease burden, and the target estimand. TMAO与腹主动脉瘤:时间排列、基线疾病负担和目标估计。
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-29 DOI: 10.1093/eurheartj/ehag688
Guo-Sheng Li, Hua-Fu Zhou, Jun Liu
{"title":"TMAO and abdominal aortic aneurysm: temporal alignment, baseline disease burden, and the target estimand.","authors":"Guo-Sheng Li, Hua-Fu Zhou, Jun Liu","doi":"10.1093/eurheartj/ehag688","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag688","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study. 修正:PCSK9抑制剂治疗动脉粥样硬化性心血管疾病但无缺血性事件的患者的疗效:一项观察性研究。
IF 45.3 1区 医学
European Heart Journal Pub Date : 2026-09-28 DOI: 10.1093/eurheartj/ehag791
{"title":"Correction: PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.","authors":"","doi":"10.1093/eurheartj/ehag791","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag791","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书